KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q3 2025 value amounting to $137.3 million.

  • Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) rose 681.08% to $137.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.3 million, marking a year-over-year increase of 681.08%. This contributed to the annual value of $127.7 million for FY2024, which is 219.77% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $137.3 million for Q3 2025, which was up 681.08% from $130.6 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $137.3 million during Q3 2025, and its lowest value of $117.1 million during Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $124.7 million, with its median value being $124.7 million (2023).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) surged by 750.7% in 2023 and then plummeted by 209.16% in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $118.5 million in 2021, then grew by 2.73% to $121.7 million in 2022, then grew by 2.64% to $124.9 million in 2023, then increased by 2.2% to $127.7 million in 2024, then grew by 7.6% to $137.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $137.3 million for Q3 2025, versus $130.6 million for Q2 2025 and $129.7 million for Q1 2025.